Kalm Therapeutics is a pre-clinical drug development company focused on a medicated, controlled-release patch for non-steroidal treatment of mild to moderate atopic dermatitis and psoriasis. The Kalm Patch uses “Continuous Dose” technology to deliver an anti-inflammatory natural medication while protecting skin from itching and infection. The patch administers its natural compound over 24 hours, providing an alternative to topical steroids that require three to five daily applications. The company emerged from stealth in 2024 and is led by founder AJ Singhal, CTO, and is based in Huntsville, AL. Kalm plans to use its seed funding to complete regulatory activities outlined in a Pre-IND meeting with the FDA, hire vital personnel, and transfer patch production to its manufacturer. Financially, the company completed a $700K Seed raise to support these near-term development and regulatory milestones.

Total raised

$1M

Funding rounds

1

Latest round

Seed

Latest activity

Aug 2024